Relief Therapeutics Holding SA / Key word(s): Personnel 03-Jun-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Announces Executive Changes GENEVA (June 3, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that interim Chief Executive Officer Michelle Lock has completed her transitional mandate with the Company. Her contract was not renewed upon its expiration on May 31, 2024. Ms. Lock will also not stand for re-election as a member of the Company’s Board of Directors at the upcoming annual general meeting. Additionally, Andrew Einhorn and Melinda Keegan have transitioned out as chief financial officer and chief human resources officer, respectively. Jeremy Meinen will continue with the Company in a senior role. Moving forward, the Company’s Board of Directors is fully committed to maximizing the value of Relief Therapeutics’ portfolio of therapeutic products. It will undertake a comprehensive review of all options to ensure the Company’s senior management team is appropriately sized with the necessary capabilities to deliver meaningful positive results. For the time being, the Board of Directors will be responsible for overseeing the functioning of the Company and day-to-day activities will continue uninterrupted. ABOUT RELIEF THERAPEUTICS CONTACT: DISCLAIMER Additional features: File: Ad hoc End of Inside Information |
Novartis returns for another piece of IFM Therapeutics
After buying a portion of IFM Therapeutics’ pipeline in 2019, Novartis is back for a second helping as it bags its STING antagonists. The Swiss